An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avadomide (Primary) ; Durvalumab (Primary) ; Golcadomide (Primary) ; Iberdomide (Primary) ; Ibrutinib (Primary) ; Lisocabtagene-maraleucel (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms PLATFORM
Sponsors Celgene Corporation

23 Mar 2023 Status changed from active, no longer recruiting to completed.
13 Jan 2023 Planned End Date changed from 21 Jul 2025 to 31 Jan 2023.
13 Jan 2023 Planned primary completion date changed from 21 Jul 2025 to 31 Jan 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com